# Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

> **NCT02673333** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 39 (actual)

## Conditions studied

- Adrenocortical Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02673333
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-02
- **Primary completion:** 2019-01-11
- **Final completion:** 2027-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02673333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02673333, "Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02673333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*